<DOC>
	<DOC>NCT01160861</DOC>
	<brief_summary>This is a Phase Ib, randomized, blinded, placebo-controlled, multiple-ascending dose study in patients with seasonal or perennial allergic rhinitis to investigate the safety, tolerability, and pharmacokinetics (PK) of MEMP1972A.</brief_summary>
	<brief_title>A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Diagnosis of allergic rhinitis In good health, determined by no clinically significant findings from medical history, 12lead ECG, and vital signs Males or females who are surgically sterilized, post menopausal for the past year, or are using two acceptable methods of contraception against pregnancy through at least 6 months after the dose of study drug History or clinical manifestations of significant metabolic, hepatic, renal, hematologic, immunodeficiency, pulmonary, cardiovascular, gastrointestinal, urologic, neurologic, or psychiatric disorders History of anaphylaxis, hypersensitivity or drug allergies Use of a nonbiologic investigational drug or participation in an investigational study with a nonbiologic drug within 30 days prior to dosing Use of a biologic investigational therapy or participation in an investigational study involving biologic therapy within 3 months prior to dosing Positive blood test for chronic viral infections by: hepatitis B surface antigen, hepatitis C virus antibody, or HIV antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>